Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and tolerability of the combination of Gleevec and
Gemzar in patients with ovarian cancer, who have progressed after receiving at least one
prior chemotherapy treatment. Gleevec is an oral chemotherapy drug used is this study and
Gemzar is an IV chemotherapy drug used. Participation in the treatment portion of the study
will continue as long as the patient's tumors shrink or remain stable and as long as the
patient is able to tolerate the study drug. The follow-up portion of the study will last for
5 years.
Phase:
Phase 2
Details
Lead Sponsor:
Henry M. Jackson Foundation for the Advancement of Military Medicine